Activity of gemcitabine and carboplatin in advanced non-small cell lung cancer: a phase II trial

被引:14
作者
Masotti, A
Zannini, G
Gentile, A
Morandini, G
机构
[1] Div Pneumol, Verona, Italy
[2] Eli Lilly Italia, Florence, Italy
关键词
carboplatin; gemcitabine; non-small cell lung cancer; phase II;
D O I
10.1016/S0169-5002(01)00452-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This phase II trial was designed to investigate the efficacy and tolerability of gemcitabine combined with carboplatin in patients with advanced or metastatic NSCLC. Patients were treated with gemcitabine 1000 mg/m(2) on days 1, 8, and 15 of a 28-day cycle and carboplatin AUC 5 mg/ml/min on day 2 of each cycle. Fifty patients (Zubrod-ECOG-WHO performance status 01 in 70/30%, stage IV disease in 64%) entered the study and were evaluable for response and toxicity. There was I complete response and 24 partial responses among 50 evaluable patients, for a response rate of 50% (95% CI: 36.0-64.1%). The median survival time was 13 months (range: 6-22 months), and the 1-year survival rate was 54%. Hematologic toxicities included grades 3 and 4 neutropenia in 24 and 8% of patients. respectively, and grades 3 and 4 thrombocytopenia in 48 and 8% of patients, respectively. These were without clinical sequelae. Seven (14%) patients had grade 3 nausea and vomiting. The combination of gemcitabine and carboplatin is highly active and well tolerated in patients with advanced or metastatic NSCLC. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:99 / 103
页数:5
相关论文
共 29 条
[1]   EFFICACY AND SAFETY PROFILE OF GEMCITABINE IN NON-SMALL-CELL LUNG-CANCER - A PHASE-II STUDY [J].
ABRATT, RP ;
BEZWODA, WR ;
FALKSON, G ;
GOEDHALS, L ;
HACKING, D ;
RUGG, TA .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (08) :1535-1540
[2]   Weekly gemcitabine with monthly cisplatin: Effective chemotherapy for advanced non-small-cell lung cancer [J].
Abratt, RP ;
Bezwoda, WR ;
Goedhals, L ;
Hacking, DJ .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :744-749
[3]   A COMPARISON OF THE TOXICITY AND EFFICACY OF CISPLATIN AND CARBOPLATIN IN ADVANCED OVARIAN-CANCER [J].
ADAMS, M ;
KERBY, IJ ;
ROCKER, I ;
EVANS, A ;
JOHANSEN, K ;
FRANKS, CR .
ACTA ONCOLOGICA, 1989, 28 (01) :57-60
[4]   IMPROVED THERAPEUTIC INDEX OF CARBOPLATIN PLUS CYCLOPHOSPHAMIDE VERSUS CISPLATIN PLUS CYCLOPHOSPHAMIDE - FINAL REPORT BY THE SOUTHWEST-ONCOLOGY-GROUP OF A PHASE-III RANDOMIZED TRIAL IN STAGE-III AND STAGE-IV OVARIAN-CANCER [J].
ALBERTS, DS ;
GREEN, S ;
HANNIGAN, EV ;
OTOOLE, R ;
STOCKNOVACK, D ;
ANDERSON, P ;
SURWIT, EA ;
MALVLYA, VK ;
NAHHAS, WA ;
JOLLES, CJ .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (05) :706-717
[5]   SINGLE-AGENT ACTIVITY OF WEEKLY GEMCITABINE IN ADVANCED NON-SMALL-CELL LUNG-CANCER - A PHASE-II STUDY [J].
ANDERSON, H ;
LUND, B ;
BACH, F ;
THATCHER, N ;
WALLING, J ;
HANSEN, HH .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (09) :1821-1826
[6]   Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) [J].
Antón, A ;
Díaz-Fernández, N ;
Larriba, JG ;
Vadell, C ;
Masutti, B ;
Montalar, J ;
Barneto, I ;
Artal, A ;
Rosell, R .
LUNG CANCER, 1998, 22 (02) :139-148
[7]   COMBINATION CHEMOTHERAPY VERSUS SINGLE AGENTS FOLLOWED BY COMBINATION CHEMOTHERAPY IN STAGE-IV NON-SMALL-CELL LUNG-CANCER - A STUDY OF THE EASTERN-COOPERATIVE-ONCOLOGY-GROUP [J].
BONOMI, PD ;
FINKELSTEIN, DM ;
RUCKDESCHEL, JC ;
BLUM, RH ;
GREEN, MD ;
MASON, B ;
HAHN, R ;
TORMEY, DC ;
HARRIS, J ;
COMIS, R ;
GLICK, J .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) :1602-1613
[8]  
BUNN PA, 1989, SEMIN ONCOL, V16, P27
[9]  
BUNN PA, 1989, SEMIN ONCOL, V16, P10
[10]   Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer [J].
Cardenal, F ;
López-Cabrerizo, MP ;
Antón, A ;
Alberola, V ;
Massuti, B ;
Carrato, A ;
Barneto, I ;
Lomas, M ;
García, M ;
Lianes, P ;
Montalar, J ;
Vadell, C ;
González-Larriba, JL ;
Nguyen, B ;
Artal, A ;
Rosell, R .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :12-18